You are here: Industry Insights > HIV

News List

Gilead Sciences' Pulse Survey Highlights Majority of People Living with HIV, Individuals at Risk and HIV Care Prescribers in Asia Pacific Experience Disruptions in HIV Care During COVID-19 Pandemic prnasia
November 30, 2020
Gilead Sciences, Inc. today announced findings from a pulse survey conducted to evaluate the impact of the COVID-19 pandemic on the access and delivery of care in HIV, which includes testing, treatment and prevention, in Asia Pacific.
ViiV’s cabotegravir scores breakthrough designation for HIV prevention pharmatimes
November 19, 2020
GlaxoSmithKline subsidiary ViiV Healthcare has announced that its long-acting injectable cabotegravir has scored a breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for HIV prevention.
Gilead Sciences Announces Recipients of its First Asia HIV Research Scholar Program prnasia
November 16, 2020
Gilead Sciences, Inc. today announced the recipients of its first Asia HIV Research Scholar Program. The Program awards up to US$130,000 over a period of two years to support innovative HIV scientific research led by early-career researchers from ...
Trial of new HIV PrEP medication stopped early due to effectiveness europeanpharmaceuticalreview
November 13, 2020
The trial was stopped because the data suggested that injections of the long-acting antiretroviral drug cabotegravir (CAB LA) are highly effective for HIV pre-exposure prophylaxis (PrEP) in women.
ViiV’s long-acting HIV drug beats standard of care in prevention study pharmatimes
November 12, 2020
ViiV Healthcare has announced that its long-acting injectable cabotegravir for HIV prevention demonstrated superiority compared to the current standard of treatment for women.
Indian researchers develop vaccine strategies for SARS-CoV-2, HIV viruses pharmaceutical-technology
November 11, 2020
Researchers at Indian Institute of Science’s (IISc) Molecular Biophysics Unit have announced the development of effective vaccine strategies against the SARS-CoV-2 and HIV viruses that cause Covid-19 and AIDS, respectively.
Indian scientists working on effective vaccines against COVID-19 and HIV: IISC expresspharma
November 11, 2020
The studies were published in the Journal of Biological Chemistry and the Proceedings of the National Academy of Sciences.
Study suggests dolutegravir is the optimal first-line HIV medication europeanpharmaceuticalreview
October 21, 2020
Researchers comparing dolutegravir to efavirenz suggest dolutegravir increases viral suppression and has similar rates of adverse events.
ViiV posts positive long-term data for two-drug HIV regimen Dovato pharmatimes
October 14, 2020
GlaxoSmithKline subsidiary ViiV Healthcare has reported new data for its two-drug HIV regimen Dovato, with hopes that the long-term data could encourage clinicians to switch from other triple regimen therapies.
ViiV’s two-drug HIV regimen demonstrates long-term efficacy pharmatimes
October 10, 2020
ViiV Healthcare has released long-term data for its two-drug regimen of dolutegravir plus lamivudine, which continued to offer non-inferior efficacy compared to a three-drug regimen in HIV.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 24 25 Next page